Patient info Open main menu

Micafungin 100 mg – patient leaflet, side effects, dosage

Last updated: · Text from the MHRA, as of · About this document

Medicine status: Prescription only (POM) Details

Medicine strength:
100 mg
Contains active substance:
ATC code:

Patient leaflet - Micafungin 100 mg powder for concentrate for solution for infusion

1. What Micafungin is and what it is used for

Micafungin contains the active substance micafungin. Micafungin is called an antifungal medicine because it is used to treat infections caused by fungal cells. Micafungin is used to treat fungal infections caused by fungal or yeast cells called Candida. Micafungin is effective in treating systemic infections (those that have penetrated within the body). It interferes with the production of a part of the fungal cell wall. An intact cell wall is necessary for the fungus to continue living and growing. Micafungin causes defects in the fungal cell wall, making the fungus unable to live and grow.

Your doctor has prescribed micafungin for you in the following circumstances when there are no other suitable antifungal treatments available (see section 2):

  • To treat adults, adolescents and children including neonates who have a serious

    fungal infection called invasive candidiasis (infection that has penetrated the body).

  • To treat adults and adolescents ≥ 16 years of age who have a fungal infection in the

    gullet (oesophagus) where treatment into a vein (intravenous) is appropriate.

  • To prevent infection with Candida in patients who are having a bone-marrow

    transplant or who are expected to have a neutropenia (low levels of neutrophils, a type of white blood cell) for 10 days or more.

2. What you need to know before you use Micafungin

Do not use Micafungin

  • if you are allergic to micafungin, other echinocandins (Ecalta or Cancidas) or any of

    the other ingredients of this medicine (listed in section 6).

Warnings and precautions

In rats, long-term treatment with micafungin led to liver damage and subsequent liver tumours. The potential risk of developing liver tumours in humans is not known, and your doctor will assess the benefits and risks of micafungin treatment before starting your medicine. Please tell your doctor if you have severe liver problems (e.g. liver failure or hepatitis) or have had abnormal liver function tests. During treatment your liver functions will be monitored more closely.

Talk to your doctor or pharmacist before using micafungin

  • if you are allergic to any medicine.
  • if you have haemolytic anaemia (anaemia due to breakdown of red blood cells)

    or haemolysis (breakdown of red blood cells).

  • if you have kidney problems (e.g. kidney failure and abnormal kidney function test).

    If this happens, your doctor may decide to monitor your kidney function more closely.

    Micafungin may also cause severe inflammation/eruption of the skin and mucous membranes (Stevens-Johnson syndrome, toxic epidermal necrolysis).

    Other medicines and Micafungin

    Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.

    It is especially important to inform your doctor if you are using amphotericin B desoxycholate or itraconazole (antifungal antibiotics), sirolimus (an immunosuppressant) or nifedipine (calcium channel blocker used to treat high blood pressure). Your doctor may decide to adjust the dose of these medicines.

    Micafungin with food and drink

    As micafungin is given intravenously (into a vein), no restrictions on food or drink are required.

    Pregnancy and breast-feeding

    If you are pregnant of breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Micafungin should not be used during pregnancy unless clearly necessary. If you use micafungin you should not breast-feed.

    Driving and using machines

    Micafungin is unlikely to have an effect on driving or using machines. However some people may feel dizzy when taking this medicine and if this happens to you, do not drive or use any tools or machines. Please inform your doctor if you experience any effects that may cause you to have problems with driving or using other machinery.

    Micafungin contains sodium

    This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially ‘sodium-free’.

3. How to use Micafungin

Micafungin must be prepared and given to you by a doctor or another healthcare professional. Micafungin should be administered once daily by slow intravenous (into a vein) infusion. Your doctor will determine how much micafungin you will receive each day.

Use in adults, adolescents ≥ 16 years of age and elderly

  • The usual dose to treat an invasive Candida infection is 100 mg per day for patients weighing more than 40 kg and 2 mg/kg per day for patients weighing 40 kg or less.
  • The dose to treat a Candida infection of the oesophagus is 150 mg for patients weighing more than 40 kg and 3 mg/kg per day for patients weighing 40 kg or less.
  • The usual dose to prevent invasive Candida infections is 50 mg per day for patients weighing more than 40 kg and 1 mg/kg per day for patients weighing 40 kg or less.

Use in children ≥ 4 months of age and adolescents < 16 years of age

  • The usual dose to treat an invasive Candida infection is 100 mg per day for patients weighing more than 40 kg and 2 mg/kg per day for patients weighing 40 kg or less.
  • The usual dose to prevent invasive Candida infections is 50 mg per day for patients weighing more than 40 kg and 1 mg/kg per day for patients weighing 40 kg or less.

Use in children and newborns < 4 months of age

  • The usual dose to treat an invasive Candida infection is 4-10 mg/kg per day.
  • The usual dose to prevent invasive Candida infections is 2 mg/kg per day.

If you receive more Micafungin than you should

Your doctor monitors your response and condition to determine what dose of micafungin is needed. However, if you are concerned that you may have been given too much micafungin, speak to your doctor or another healthcare professional immediately.

If you miss a dose of Micafungin

Your doctor monitors your response and condition to determine what micafungin treatment is needed.

However, if you are concerned that you may have missed a dose, speak to your doctor or another healthcare professional immediately.

If you have any further questions on the use of this product, ask your doctor or pharmacist.

Version: 00

Dimensions: 240 x 340 mm

Printing Colour: Black

The following information is intended for medical or healthcare professionals only:

Micafungin must not be mixed or co-infused with other medicinal products except those mentioned below. Using aseptic techniques at room temperature, micafungin is reconstituted and diluted as follows:

  1. 1.

    The plastic cap must be removed from the vial and the stopper disinfected with

    alcohol.

    1. 2.

      Five ml of sodium chloride 9 mg/ml (0.9%) solution for infusion or glucose

      50 mg/ml (5%) solution for infusion (taken from a 100 ml bottle/bag) should be aseptically and slowly injected into each vial along the side of the inner wall. Although the concentrate will foam, every effort should be made to minimise the amount of foam generated. A sufficient number of vials of micafungin must be reconstituted to obtain the required dose in mg (see table below).

    2. 3. The vial should be rotated gently. DO NOT SHAKE. The powder will dissolve completely. The concentrate should be used immediately. The vial is for single use only. Therefore, unused reconstituted concentrate must be discarded immediately. UK (Aspiro) Micafungin 50mg/ 100mg Leaflet

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

If you experience an allergic attack, or a severe skin reaction (e.g. blistering and peeling of the skin), you must inform your doctor or nurse immediately.

Micafungin may cause the following other side effects:

Common (may affect up to 1 in 10 people)

  • abnormal blood tests (decreased white blood cells [leucopenia; neutropenia]);

    decreased red blood cells (anaemia)

  • decreased potassium in the blood (hypokalaemia); decreased magnesium in the

    blood (hypomagnesaemia); decreased calcium in the blood (hypocalcaemia)

  • headache
  • inflammation of the vein wall (at injection-site)
  • nausea (feeling sick); vomiting (being sick); diarrhoea; abdominal pain
  • abnormal liver function tests (increased alkaline phosphatase; increased aspartate

    aminotransferase, increased alanine aminotransferase)

  • increased bile pigment in the blood (hyperbilirubinaemia)
  • rash
  • fever
  • rigors (shivering)

Uncommon (may affect up to 1 in 100 people)

  • abnormal blood tests (decreased blood cells [pancytopenia]); decreased blood

    platelets (thrombocytopenia); increases in a certain type of white blood cells called eosinophils; decreased albumin in the blood (hypoalbuminaemia)

  • hypersensitivity
  • increased sweating
  • decreased sodium in the blood (hyponatraemia); increased potassium in the blood

    (hyperkalaemia); decreased phosphates in the blood (hypophosphataemia); anorexia (eating disorder)

  • insomnia (difficulty in sleeping); anxiety; confusion
  • feeling lethargic (somnolence); trembling; dizziness; disturbed taste
  • increased heart rate; stronger heartbeat; irregular heartbeat
  • high or low blood pressure; skin flushing
  • shortness of breath
  • indigestion; constipation
  • liver failure; increased liver enzymes (gamma-glutamyltransferase); jaundice

    (yellowing of the skin or whites of the eyes caused by liver or blood problems); reduced bile reaching the intestine (cholestasis); enlarged liver; liver inflammation

  • itchy rash (urticaria); itching; skin flushing (erythema)
  • abnormal kidney function tests (increased blood creatinine; increased urea in the

    blood); aggravated kidney failure

  • increase in an enzyme called lactate dehydrogenase
  • clotting in vein at injection-site; inflammation at injection-site; pain at injection-site;

    collection of fluid in your body

Rare (may affect up to 1 in 1,000 people)

  • anaemia due to breakdown of red blood cells (haemolytic anaemia); breakdown of

    red blood cells (haemolysis)

Not known (frequency cannot be estimated from the available data)

  • disorder of blood clotting system
  • (allergic) shock
  • damage to liver cells including death
  • kidney problems; acute kidney failure

    Additional side effects in children and adolescents

    The following reactions have been reported more often in paediatric patients than in adult patients:

    Common (may affect up to 1 in 10 people)

    • decreased blood platelets (thrombocytopenia)
    • increased heart rate (tachycardia)
    • high or low blood pressure
    • increased bile pigment in the blood (hyperbilirubinaemia); enlarged liver
    • acute kidney failure; increased urea in the blood

Reporting of side effects

If you get any side effects talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via Yellow Card Scheme website www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Micafungin

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and vial after EXP. The expiry date refers to the last day of that month.

This medicine does not require any special storage conditions.

Reconstituted concentrate in vial:

Chemical and physical in-use stability has been demonstrated for up to 48 hours at 25°C when reconstituted with sodium chloride 9 mg/ml (0.9%) solution for infusion or glucose 50 mg/ml (5%) solution for infusion.

Diluted infusion solution:

Chemical and physical in-use stability has been demonstrated for up to 96 hours at 25°C and up to 24 hours at 2 – 8 °C when protected from light and when diluted with sodium chloride 9 mg/ml (0.9%) solution for infusion or glucose 50 mg/ml (5%) solution for infusion.

From a microbiological point of view, the medicinal product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2°C to 8°C, unless dilution has taken place in controlled and validated aseptic conditions.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Micafungin contains

The active substance is micafungin (as sodium).

Each vial contains 50 mg micafungin (as sodium).

Each vial contains 100 mg micafungin (as sodium).

The other ingredients are: Lactose monohydrate, citric acid anhydrous (to adjust the pH) and sodium hydroxide (to adjust the pH).

What Micafungin looks like and contents of the pack

White to off white lyophilized cake or powder.

This medicine is supplied as a single vial.

Marketing Authorisation Holder and Manufacturer

Amarox Limited

Congress House, 14 Lyon Road

Harrow, HA1 2EN

United Kingdom

This leaflet was last revised in 08/2026.

2xxxxxx

  1. 4.

    All of the reconstituted concentrate should be withdrawn from each vial and

    returned into the infusion bottle/bag from which it was originally taken. The diluted infusion solution should be used immediately. Chemical and physical in-use stability have been demonstrated for 96 hours at 25°C when protected from light and diluted as described above.

  2. 5.

    The infusion bottle/bag should be gently inverted to disperse the diluted solution but

    NOT agitated in order to avoid foaming. The solution must not be used if it is cloudy or has precipitated.

  3. 6.

    The infusion bottle/bag containing the diluted infusion solution should be inserted

    into a closable opaque bag for protection from light.

    Preparation of the solution for infusion

Dose (mg)

Micafungin vial to be used

(mg/vial)

Volume of sodium chloride (0.9%) or glucose (5%) to be added per vial

Volume

(concentration) of reconstituted powder

Standard infusion (added up to

100 ml) Final concentration

501 x 505 mlapprox. 5 ml (10 mg/ml)0.5 mg/ml
1001 x 1005 mlapprox. 5 ml (20 mg/ml)1.0 mg/ml

About this document

Source: MHRA - Medicines and Healthcare products Regulatory Agency (products.mhra.gov.uk) · Marketing authorisation: PL 49445/0420

Last revision stated in the text: August 2026 · MHRA data as of 13 October 2026

Found a mistake? Tell us on the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Facts about Micafungin 100 mg powder for concentrate for solution for infusion

Prescription needed? Yes, prescription-only medicine (POM)
Active substance Micafungin
Strength 100 mg
Pharmaceutical form Powder for solution for infusion
A white colour lyophilized powder or cake
How is it taken Intravenous
Excipients Lactose Monohydrate, Citric Acid Anhydrous (to adjust the pH), Sodium Hydroxide (to adjust the pH)
Is it available? Listed as available (NHS Dictionary of Medicines and Devices – not a record of current supplies)
Shelf life Unopened vial: 3 years.
Reconstituted concentrate in vial
Chemical and physical in-use stability has been demonstrated for up to 48 hours at 25°C when reconstituted with sodium chloride 9 mg/ml (0.9%) solution for infusion or glucose 50 mg/ml (5%) solution for infusion.
Diluted infusion solution
Chemical and physical in-use stability has been demonstrated for 96 hours at 25°C when protected from light when diluted with sodium chloride 9 mg/ml (0.9%) solution for infusion or glucose 50 mg/ml (5%) solution for infusion. Micafungin contains no preservatives. From a microbiological point of view, the reconstituted and diluted solutions should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8°C, unless the reconstitution and dilution have taken place in controlled and validated aseptic conditions.
Storage Unopened vials
Store below 25°C.
For storage conditions after reconstitution and dilution of the medicinal product, see section 6.3.
Drug group (ATC) Antimycotics for systemic use, other antimycotics for systemic use
  1. J Antiinfectives for systemic use
    1. J02 Antimycotics for systemic use
      1. J02A Antimycotics for systemic use
        1. J02AX Other antimycotics for systemic use
          1. J02AX05 micafungin
Marketing authorisation PL 49445/0420, PL 58839/0073 (first authorised 21 January 2026)
Marketing authorisation holder Zydus Pharmaceuticals UK Ltd
Codes BNF 05020400

Sources: the MHRA product information (products.mhra.gov.uk) and the NHS Dictionary of Medicines and Devices (dm+d), release 10.2.0 of 19 October 2026, NHS Business Services Authority. Contains public sector information licensed under the Open Government Licence v3.0.